依折麦布联合阿托伐他汀对急性冠状动脉综合征患者血脂指标及血管内皮功能的影响  

Effect of atorvastatin co-administration with ezetimibe on lipid and vascular endothelial function in patients with acute coronary syndrome

作　　者：俞章平 余晗俏 钟忆周 梁亚非[1] 高文涛[2] 

机构地区：[1]金华市人民医院心内科,浙江金华321000 [2]南京医科大学医学科学部,江苏南京210029

出　　处：《中国生化药物杂志》2014年第6期110-112,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家自然科学基金(81172267)

摘　　要：目的 探讨依折麦布联合阿托伐他汀对急性冠状动脉综合征(acute coronary syndrome,ACS)患者血脂及血管内皮功能的影响.方法 选取2011年3月～2014年3月金华市人民医院收治的ACS患者180例,随机分为对照组和观察组,每组90例.观察组给予阿托伐他汀片(口服,20 mg/d)联合服用依折麦布片(口服,10 mg/d).对照组给予阿托伐他汀片(口服,20 mg/d).对比2组患者治疗前后血脂、血清内皮素1(endothelin-1,ET-1)、一氧化氮(nitricoxide,NO)水平变化及不良反应情况.结果 治疗后观察组LDL-C为(2.08±1.22) mol/L、TC为(3.18±1.28) mol/L,均明显低于对照组的(3.16±1.95) mol/L、(4.15±2.07) mol/L,差异有统计学意义(P＜0.05).治疗后观察组ET-1为(3.06±1.18) pg/mL,低于对照组的(4.24±1.32) pg/mL,差异有统计学意义(P＜0.05).治疗后观察组NO为(83.13±1.81) μmol/L,高于对照组的(74.28±2.13) μmol/L,差异有统计学意义(P＜0.05).结论 依折麦布联合阿托伐他汀对急性冠状动脉综合征的临床效果良好.Objective To explore the effectiveness of atorvastatin co-administration with ezetimibe on lipid and vascular endothelial function in patients with acute coronary syndrome( ACS). Methods 180 cases from March 2011 to March 2014 were selected and randomly divided into two groups,the control group( n = 90) and the observation group( n = 90). The patients in the observation group were treated by atorvastatin tablets( oral,20 mg /day) co-administration with ezetimibe tablets( oral,10 mg /day),while the patients in the control group were treated by atorvastatin tablets( oral,20 mg /day). Changes in blood lipids,serum endothelin-1( ET-1),nitric oxide( NO) and adverse reactions were compared in two groups before and after treatment. Results After treatment,the level of LDL-C was( 2. 08 ± 1. 22) mmol /L and TC was( 3. 18 ± 1. 28) mmol /L in observation group,which were lower than( 3. 16 ± 1. 95) mmol /L and( 4. 15 ± 2. 07) mmol /L in control group,the differences were all statistically significant( P < 0. 05).After treatment,the ET-1 in observation group was( 3. 06 ± 1. 18) pg /mL,lower than( 4. 24 ± 1. 32) pg /mL in control group,the difference was statistically significant( P < 0. 05). After treatment,the NO in the observation group was( 83. 13 ± 1. 81) μmol /L,higher than( 74. 28 ± 2. 13) μmol /L in control group,the difference was statistically significant( P < 0. 05). Conclusion Clinical efficacy of ezetimibe combined with atorvastatin is good in treatment of acute coronary syndrome.

关 键 词：急性冠状动脉综合征 依折麦布 阿托伐他汀 

分 类 号：R459.1[医药卫生—治疗学]